Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Core Viewpoint - Biofrontera Inc. will participate in the Lytham Partners Fall 2025 Investor Conference, engaging in a webcast presentation and one-on-one meetings with investors on September 30, 2025 [1][2][3]. Company Overview - Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatological conditions, particularly through photodynamic therapy (PDT) [4]. - The company commercializes Ameluz, a drug-device combination used with the RhodoLED lamp series for treating actinic keratosis (AK) and pre-cancerous skin lesions [4]. - Biofrontera is conducting clinical trials to expand the application of its products to treat non-melanoma skin cancers and moderate to severe acne [4].